Media and News
Rochester, NY, January 25th. 2008: PharmaNova, Inc. Appoints Deepak Thassu as Vice-President, Pharmaceutical Development.
Press release: Rochester, NY, January 25th. 2008. PharmaNova, Inc. Appoints Deepak Thassu as Vice-President, Pharmaceutical Development.
PharmaNova Inc. announced today that it has hired Deepak Thassu Ph.D. MBA., a nanotechnology and drug delivery specialist to further strengthen its competitive position in the area of next generation pharmaceuticals and product development technologies.
Dr. Thassu joins PharmaNova as Vice President Pharmaceutical Development, from Holopack International Corporation where he was Chief Scientific Officer. He has 18 years of pharmaceutical R & D product development experience with several leading international pharmaceutical companies, and specializes in novel drug delivery systems with emphasis on the oral and transdermal delivery of a wide variety of pharmaceuticals. Deepak is an inventor on multiple US and EU drug delivery and formulation patents and is the author and/or editor of several books and book chapters. His first book in the area of (pharmaceutical) nanotechnology, “Nanoparticulate Drug Delivery Systems,” was published in 2007.
PharmaNova President Rodney Brown said “We are very fortunate and privileged to have Dr. Thassu join our team. His experience in sustained release technologies and nanoparticle drug delivery will have an immediate impact in accelerating the development of PharmaNova’s platform technologies and our innovative product portfolio.”
Dr. Thassu said “The development of new drug delivery technologies is fundamental to the success of technology-based companies worldwide. The science of nanoparticle technology has great potential to generate complementary, convergent technologies and to accelerate the development of truly innovative pharmaceuticals -- and biopharmaceuticals -- at PharmaNova. I’m truly delighted to be part of the PharmaNova team and looking forward to contributing to the growth of this exciting company.
PharmaNova Inc. is a privately held, specialty drug development company founded on the re-purposing and enhancement of known drugs using proprietary nanoparticle and other complementary formulation technologies. PharmaNova specializes in low risk, fast to market products and generates revenue from partnering and licensing strategies with commercialization partners worldwide. The company’s current focus is on extraordinary value products in Women’s Health and adjacent areas, including a non-hormonal treatment for hot flashes associated with menopause, and for vasomotor symptoms secondary to the treatment of certain cancers. Our nanoparticle technology is currently employed in the development of improved drug products such as cancer chemotherapeutics.
For further information contact:
PharmaNova: Technology for Better Medicines
« Back to Media
Member of the media wishing to learn more about Pharmanova should contact:
Rafael Larramendi, President | Rafael.firstname.lastname@example.org | (585) 413-4721.